List of Excipients in Branded Drug NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE COLD AND SINUS

Generic Drugs Containing NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE COLD AND SINUS

Company	Ingredient	NDC	Excipient
VESPYR BRANDS INC	naproxen sodium and pseudoephedrine hydrochloride	71179-816	CROSCARMELLOSE SODIUM
VESPYR BRANDS INC	naproxen sodium and pseudoephedrine hydrochloride	71179-816	FERRIC OXIDE YELLOW
VESPYR BRANDS INC	naproxen sodium and pseudoephedrine hydrochloride	71179-816	HYPROMELLOSE
VESPYR BRANDS INC	naproxen sodium and pseudoephedrine hydrochloride	71179-816	HYPROMELLOSE 2208
VESPYR BRANDS INC	naproxen sodium and pseudoephedrine hydrochloride	71179-816	HYPROMELLOSE 2910

What are the Most Frequently-Used Excipients in NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE COLD AND SINUS?

# Of NDCs	Excipient
1	CROSCARMELLOSE SODIUM
1	FERRIC OXIDE YELLOW
1	HYPROMELLOSE
1	HYPROMELLOSE 2208
1	HYPROMELLOSE 2910

Excipient Strategy and Commercial Opportunities for Naproxen Sodium and Pseudoephedrine Hydrochloride Cold and Sinus Products

Last updated: August 9, 2026

Naproxen sodium 220 mg plus pseudoephedrine hydrochloride 120 mg is a mature oral cold-and-sinus combination built around two different release requirements: rapid analgesic and anti-inflammatory activity from naproxen sodium, and prolonged nasal decongestant activity from extended-release pseudoephedrine. The principal commercial opportunity is not new chemical matter. It is differentiated delivery, improved tolerability, simplified dosing, lower manufacturing cost, and private-label distribution.

In the United States, the reference commercial concept is an extended-release tablet comparable to Aleve-D Sinus & Cold. Naproxen sodium is an OTC analgesic active ingredient, while pseudoephedrine hydrochloride is an OTC nasal decongestant subject to federal retail controls and purchase restrictions under the Combat Methamphetamine Epidemic Act.[1,2]

What is the active-ingredient and dosage-form profile?

The typical product contains:

Parameter	Naproxen sodium	Pseudoephedrine hydrochloride
Typical unit strength	220 mg	120 mg
Pharmacologic role	Analgesic, antipyretic, anti-inflammatory	Nasal decongestant
Release requirement	Immediate or rapid release	Extended release
Typical dosing interval	8 to 12 hours	Approximately 12 hours
Primary formulation challenge	Rapid dissolution with gastrointestinal tolerability	Controlled release over an extended period
Regulatory category	OTC analgesic	OTC nasal decongestant with retail controls

The combination is technically challenging because the product must deliver two active ingredients with different dissolution profiles from a single tablet. A simple immediate-release blend can produce excessive pseudoephedrine exposure early in the dosing interval and fail to provide 12-hour decongestant coverage. A fully sustained-release matrix can delay naproxen onset.

The most commercially practical architecture is a multilayer tablet, coated multiparticulate system, or matrix tablet that gives naproxen sodium an early release profile while controlling pseudoephedrine release.

What excipients are used in naproxen sodium and pseudoephedrine products?

Public labeling for branded extended-release combination tablets identifies conventional excipients such as microcrystalline cellulose, croscarmellose sodium, hypromellose, povidone, magnesium stearate, colloidal silicon dioxide, sodium lauryl sulfate, talc, and titanium dioxide.[3]

The precise composition varies by manufacturer and may change with manufacturing-site transfers, scale-up, or regulatory supplements.

Functional excipient map

Excipient class	Typical examples	Primary function	Strategic relevance
Diluent	Microcrystalline cellulose	Tablet mass and compressibility	Supports robust direct compression
Superdisintegrant	Croscarmellose sodium	Rapid tablet breakup	Useful for the naproxen layer
Hydrophilic polymer	Hypromellose	Release control and film coating	Controls pseudoephedrine release
Binder	Povidone	Granule and tablet strength	Reduces friability during high-speed compression
Lubricant	Magnesium stearate	Ejection and tooling protection	Excess levels can slow dissolution
Glidant	Colloidal silicon dioxide	Powder flow and content uniformity	Important for multilayer or low-dose blends
Wetting agent	Sodium lauryl sulfate	Improves wetting and dissolution	Relevant to naproxen sodium dispersion
Coating agents	Talc, titanium dioxide, hypromellose	Protection, appearance, swallowability	Supports product differentiation and stability
pH modifier or buffer	Product-specific	Controls microenvironmental pH	Can influence naproxen dissolution and stability

Naproxen sodium is more water-soluble than naproxen, but its dissolution can still be affected by particle size, compaction force, wetting, and excipient selection. Pseudoephedrine hydrochloride is highly water-soluble, making release control the central formulation problem.

What excipient strategy best supports a commercial product?

A successful formulation should separate the release-control functions of the two actives rather than forcing a single excipient system to control both.

Immediate-release naproxen phase

The naproxen phase should prioritize:

• rapid wetting and dispersion;
• low lubricant loading;
• sufficient tablet strength;
• control of tablet hardness and friability;
• compatibility with the pseudoephedrine release-control phase.

Microcrystalline cellulose, croscarmellose sodium, povidone, and colloidal silicon dioxide are conventional choices. Sodium lauryl sulfate or another wetting agent can improve reproducibility when naproxen sodium particle properties vary.

The formulation risk is over-compression. A hard, low-porosity tablet can delay naproxen release even when the formulation contains a superdisintegrant.

Extended-release pseudoephedrine phase

Pseudoephedrine control can be achieved through:

1. hydrophilic matrix technology using hypromellose;
2. polymer-coated granules or pellets;
3. coated ion-exchange or multiparticulate systems;
4. bilayer or press-coated tablets;
5. osmotic or membrane-controlled systems.

Hydrophilic hypromellose matrices are usually the lowest-cost path. They are compatible with high-volume tablet manufacturing and can provide sustained release through polymer hydration, gel formation, diffusion, and erosion.

Multiparticulate systems offer a more consistent gastrointestinal release profile and may reduce the impact of tablet breakage. They also create stronger product differentiation, but manufacturing is more complex and cost per unit is generally higher.

Bilayer and multilayer tablets

A bilayer design is commercially attractive because it allows:

• immediate-release naproxen sodium in one layer;
• extended-release pseudoephedrine in the second layer;
• independent optimization of each active;
• lower risk of direct excipient incompatibility;
• a differentiated product profile.

The main manufacturing risks are layer weight variation, interfacial bonding, cross-contamination, and poor compression balance. A multilayer tablet can also create more demanding process-validation requirements than a conventional monolayer tablet.

What formulation patents are likely to protect the product?

The strongest protectable subject matter is usually the delivery system rather than the active ingredients.

Potential claim categories include:

Claim category	Commercial value	Typical vulnerability
Bilayer tablet architecture	High if release profiles are difficult to reproduce	Design-around through coated particles or matrix technology
Specific hypromellose grade and concentration	Moderate	Substitution with another polymer or viscosity grade
Pseudoephedrine multiparticulates	Moderate to high	Alternative coating composition
Defined dissolution profile	High if linked to clinical or pharmacokinetic performance	Invalidity or non-infringement disputes over test conditions
Excipients and ratios	Low to moderate	Easy substitution unless the combination is functionally necessary
Manufacturing process	Moderate	Process changes may avoid literal infringement
Stability system	Moderate	Alternative packaging, antioxidants, or moisture control
Method of treating sinus congestion and pain	Low for mature OTC combinations	Regulatory and patentability limitations

The active ingredients are old and widely used. A new patent position would therefore need to rely on a novel formulation, release mechanism, manufacturing process, dosage regimen, or clinically meaningful performance characteristic.

How strong is the patent estate?

The patent estate for a conventional naproxen sodium and pseudoephedrine hydrochloride tablet is likely to be weaker than the estate for a new molecular entity or complex drug-delivery platform. The main barriers are:

• extensive prior art covering naproxen, pseudoephedrine, and sustained-release tablets;
• predictable use of hypromellose and conventional compression technology;
• availability of multiple non-infringing formulation routes;
• limited value of broad claims directed only to the active-ingredient combination.

A stronger estate would require narrow but difficult-to-design-around claims covering a specific release architecture, dissolution window, pharmacokinetic profile, or manufacturing sequence.

What is the FDA and Orange Book status?

The product can enter the U.S. market through different regulatory routes.

OTC monograph pathway

The FDA’s OTC monograph system covers established categories for analgesics and nasal decongestants, subject to ingredient, labeling, dosage, and safety conditions.[1] A monograph-based product generally does not receive the same Orange Book patent-certification framework as a prescription product approved under a conventional NDA.

NDA pathway

A branded extended-release combination may be approved under an NDA when the sponsor relies on a specific formulation, dosage form, combination, or clinical development package. If the product is approved under an NDA, the Orange Book may contain the applicable product and any eligible listed patents.[4]

Orange Book listing should be reviewed at the specific product level. It is not appropriate to infer patent coverage solely from the presence of naproxen sodium or pseudoephedrine in the formulation.

Paragraph IV challenges

A generic applicant filing an ANDA for an NDA-approved product would review listed patents and submit the applicable patent certifications. A Paragraph IV certification could trigger patent litigation within the statutory period and may create a 30-month stay of approval under the Hatch-Waxman framework.[5]

For a monograph-based OTC product, the commercial challenge is different. The applicant would focus on compliance with the monograph or on an alternative approval pathway, with formulation patents creating the primary litigation exposure.

When does exclusivity expire?

Chemical and commercial exclusivity for these actives expired long ago. Any remaining protection would come from:

• product-specific formulation patents;
• extended-release delivery patents;
• method-of-use patents;
• regulatory exclusivity associated with a particular NDA;
• trademark and trade-dress rights;
• manufacturing know-how.

A generic or private-label entrant does not need to reproduce the reference excipient formula. It needs to meet the applicable quality, dissolution, stability, labeling, and bioavailability requirements while avoiding enforceable patent claims.

What generic entry risks exist?

Generic entry risk is high for a conventional immediate-release combination and moderate for a technically robust extended-release product.

Low-barrier entry scenarios

A competitor may commercialize:

• a conventional tablet using a different filler and disintegrant;
• a separate naproxen product and pseudoephedrine product;
• a private-label equivalent under a monograph or approved application;
• a product with a different coating system;
• a comparable 12-hour release profile using another hydrophilic polymer.

Higher-barrier entry scenarios

Entry becomes more difficult when the reference product has:

• a narrow pseudoephedrine dissolution profile;
• a multilayer tablet with complex manufacturing controls;
• a validated pharmacokinetic relationship between dissolution and exposure;
• formulation patents covering specific polymer ratios;
• an approved product-specific combination not readily supported by monograph conditions.

The most credible generic launch strategy is usually a design-around formulation using a different matrix former, coated granule system, or bilayer compression process.

Which excipient innovations create commercial opportunities?

Abuse-deterrent and diversion-aware pseudoephedrine formats

Pseudoephedrine is subject to purchase limits, identification requirements, and sales-record obligations.[2] A formulation that reduces tampering, improves package accountability, or supports pharmacist-controlled distribution could create value, although the formulation alone does not eliminate statutory retail controls.

Smaller tablets and improved swallowability

The combination requires a relatively high total active mass. A higher-density formulation, multilayer design, or mini-tablet approach could reduce tablet size and improve patient acceptance.

Extended-release liquid or softgel products

A liquid or softgel could address consumers who have difficulty swallowing tablets. The main challenges are:

• maintaining a 12-hour pseudoephedrine release profile;
• preventing naproxen precipitation;
• controlling taste and irritation;
• achieving long-term chemical and physical stability;
• meeting child-resistant packaging requirements.

Lower gastrointestinal burden

Naproxen has established gastrointestinal and cardiovascular safety concerns at the active-ingredient level.[6] An excipient cannot remove those risks, but a formulation can improve dissolution consistency, reduce local concentration spikes, and support lower effective dosing. Claims must remain consistent with FDA labeling and cannot imply a safety advantage without supporting evidence.

Moisture and temperature robustness

A moisture-resistant coating, high-barrier bottle, or blister package may reduce pseudoephedrine migration, coating defects, and dissolution drift. This is commercially relevant for private-label products distributed through broad retail channels.

Brand and private-label flexibility

A manufacturer can use the same core tablet with different:

• film-coat colors;
• imprinting;
• packaging formats;
• count sizes;
• child-resistant closures;
• retailer-specific labels.

This creates a scalable platform for pharmacy, club-store, grocery, and e-commerce channels.

How does this product compare with competing cold-and-sinus products?

Product type	Analgesic	Decongestant	Main advantage	Main limitation
Naproxen sodium plus pseudoephedrine	Naproxen sodium	Pseudoephedrine	Long analgesic duration with systemic decongestion	NSAID and stimulant-related warnings
Ibuprofen plus pseudoephedrine	Ibuprofen	Pseudoephedrine	Familiar analgesic and decongestant combination	Shorter ibuprofen dosing interval in some products
Acetaminophen plus phenylephrine	Acetaminophen	Phenylephrine	Broad OTC familiarity and fewer pseudoephedrine purchase restrictions	Oral phenylephrine effectiveness has been questioned by FDA review
Naproxen sodium alone	Naproxen sodium	None	Analgesic and anti-inflammatory activity	Does not address nasal congestion
Pseudoephedrine alone	None	Pseudoephedrine	Targeted decongestant therapy	Does not treat pain or fever

The combination is best positioned for adults seeking long-duration treatment of pain, fever, sinus pressure, and nasal congestion. It is less attractive for consumers with NSAID contraindications, uncontrolled hypertension, cardiovascular disease, or stimulant sensitivity.

What manufacturing and intellectual-property barriers matter?

Manufacturing barriers are more important than raw-material scarcity. Both active ingredients are mature, globally sourced APIs. The principal technical controls are:

• segregation and containment of pseudoephedrine;
• uniform distribution of the two active ingredients;
• bilayer weight control;
• polymer hydration and release consistency;
• tablet hardness and friability;
• coating uniformity;
• dissolution across pH conditions;
• packaging moisture protection;
• validated cleaning procedures.

Pseudoephedrine also creates supply-chain and compliance obligations because of diversion controls. A contract manufacturer must manage procurement records, inventory reconciliation, storage security, and customer qualification.

Trade secrets may therefore provide more practical protection than patents. These can include granulation endpoint, polymer hydration conditions, coating parameters, compression force, tooling configuration, and dissolution-control methods.

What licensing and partnership opportunities exist?

The most realistic licensing opportunities concern technology and distribution rather than the active ingredients.

Potential transactions include:

1. licensing a controlled-release pseudoephedrine platform;
2. acquiring a private-label-ready finished dosage form;
3. partnering with a manufacturer that has pseudoephedrine compliance infrastructure;
4. licensing a pediatric or swallowability-focused dosage form;
5. using a retailer-specific commercialization agreement;
6. acquiring regional rights to an OTC brand or authorized generic;
7. outsourcing packaging and distribution while retaining formulation ownership.

A licensee should evaluate freedom to operate around the release mechanism, trademark rights, regulatory file ownership, manufacturing-site qualification, and the ability to change excipients without a new approval or stability program.

What revenue exposure and market opportunities are most attractive?

The product has limited opportunity for premium pricing based on active-ingredient novelty. Revenue depends on retail placement, brand recognition, dosage convenience, supply reliability, and private-label economics.

The most attractive opportunities are:

• authorized generic supply;
• retailer-exclusive packaging;
• club-store multipacks;
• pharmacy-counter distribution;
• 12-hour convenience positioning;
• smaller or easier-to-swallow tablets;
• high-barrier packaging;
• export markets where pseudoephedrine controls differ;
• contract manufacturing for regional brands.

The highest-margin strategy is likely a differentiated formulation with defensible manufacturing know-how. The lowest-risk strategy is a conventional equivalent with efficient sourcing and broad retail distribution.

Key Takeaways

• The commercial value lies in controlled pseudoephedrine release, not in the mature active ingredients.
• A bilayer or multiparticulate dosage form provides the clearest formulation differentiation.
• Hypromellose, microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate, and colloidal silicon dioxide support a conventional cost-efficient platform.
• Formulation patents may protect release architecture, dissolution performance, or manufacturing processes, but broad active-ingredient claims are unlikely to provide meaningful protection.
• Generic entry risk is high unless the product has narrow release specifications, complex manufacturing, or enforceable formulation claims.
• Pseudoephedrine retail controls create operational barriers and potential compliance value for experienced manufacturers.
• The strongest commercial opportunities are private label, authorized generic supply, improved swallowability, packaging differentiation, and controlled-release technology licensing.
• Orange Book and Paragraph IV analysis must be conducted against the specific NDA and product listing, not against the active ingredients alone.

FAQs

Can naproxen sodium and pseudoephedrine hydrochloride be formulated in one immediate-release tablet?

Yes, but an immediate-release tablet may not provide the desired 12-hour pseudoephedrine effect. A controlled-release phase is generally preferable when the product is positioned for extended dosing.

Which polymer is most practical for 12-hour pseudoephedrine release?

Hypromellose is the most conventional starting point because it is widely used, scalable, and compatible with matrix-tablet manufacturing. A final selection depends on polymer viscosity, concentration, tablet geometry, compression force, and dissolution targets.

Can a competitor use different excipients and still make an equivalent product?

Yes. Generic and private-label manufacturers generally do not need to copy the reference excipient list. They must meet applicable regulatory, quality, dissolution, stability, and bioavailability requirements and avoid enforceable formulation claims.

Does pseudoephedrine require special manufacturing controls?

Yes. Manufacturing and distribution must account for federal and state requirements addressing procurement, storage, inventory control, transaction records, and diversion prevention.[2]

Is a softgel formulation commercially superior to a tablet?

Not necessarily. A softgel may improve swallowability and consumer differentiation, but maintaining extended pseudoephedrine release, controlling naproxen compatibility, and achieving acceptable stability can increase development and manufacturing costs.

References

1. U.S. Food and Drug Administration. (2024). OTC monograph M012: Internal analgesic, antipyretic, and antirheumatic drug products. FDA.

2. U.S. Drug Enforcement Administration. (2024). Retail sales of scheduled listed chemical products and pseudoephedrine requirements. U.S. Department of Justice.

3. DailyMed. (n.d.). Aleve-D Sinus & Cold: Naproxen sodium and pseudoephedrine hydrochloride extended-release tablet labeling. National Library of Medicine.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. U.S. Code. (2023). 21 U.S.C. § 355: New drugs; abbreviated applications; patent certifications and approval stays.

6. U.S. Food and Drug Administration. (2023). Naproxen and nonsteroidal anti-inflammatory drug labeling and safety information. FDA.